Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.
Revenue (Most Recent Fiscal Year) | $26.82M |
Net Income (Most Recent Fiscal Year) | $-352.09M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 66.64 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.19 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -1312.64% |
Net Margin (Trailing 12 Months) | -1312.64% |
Return on Equity (Trailing 12 Months) | -38.08% |
Return on Assets (Trailing 12 Months) | -33.69% |
Current Ratio (Most Recent Fiscal Quarter) | 12.27 |
Quick Ratio (Most Recent Fiscal Quarter) | 11.99 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | 0.18 |
Book Value per Share (Most Recent Fiscal Quarter) | $14.51 |
Earnings per Share (Most Recent Fiscal Quarter) | $-1.72 |
Earnings per Share (Most Recent Fiscal Year) | $-6.33 |
Diluted Earnings per Share (Trailing 12 Months) | $-6.34 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 56.19M |
Free Float | 53.81M |
Market Capitalization | $1.79B |
Average Volume (Last 20 Days) | 0.63M |
Beta (Past 60 Months) | 0.83 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 4.24% |
Percentage Held By Institutions (Latest 13F Reports) | -- |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |